402 related articles for article (PubMed ID: 11590814)
21. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
Zagars GK; Pollack A; von Eschenbach AC
Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
[TBL] [Abstract][Full Text] [Related]
22. Radical prostatectomy for clinical stage T3a disease.
Freedland SJ; Partin AW; Humphreys EB; Mangold LA; Walsh PC
Cancer; 2007 Apr; 109(7):1273-8. PubMed ID: 17315165
[TBL] [Abstract][Full Text] [Related]
23. Natural history of progression after PSA elevation following radical prostatectomy.
Pound CR; Partin AW; Eisenberger MA; Chan DW; Pearson JD; Walsh PC
JAMA; 1999 May; 281(17):1591-7. PubMed ID: 10235151
[TBL] [Abstract][Full Text] [Related]
24. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results.
Roehl KA; Han M; Ramos CG; Antenor JA; Catalona WJ
J Urol; 2004 Sep; 172(3):910-4. PubMed ID: 15310996
[TBL] [Abstract][Full Text] [Related]
25. Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy.
Tollefson MK; Slezak JM; Leibovich BC; Zincke H; Blute ML
Mayo Clin Proc; 2007 Apr; 82(4):422-7. PubMed ID: 17418069
[TBL] [Abstract][Full Text] [Related]
26. Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer.
Khan MA; Partin AW; Mangold LA; Epstein JI; Walsh PC
Urology; 2003 Nov; 62(5):866-71. PubMed ID: 14624910
[TBL] [Abstract][Full Text] [Related]
27. Implications of greater short-term PSA recurrence with laparoscopic as compared to retropubic radical prostatectomy for Japanese clinically localized prostate carcinomas.
Akita H; Okamura T; Ando R; Nagata D; Naruyama H; Yamada Y; Naiki T; Yasui T; Tozawa K; Kohri K
Asian Pac J Cancer Prev; 2011; 12(11):2959-61. PubMed ID: 22393971
[TBL] [Abstract][Full Text] [Related]
28. Postoperative radiotherapy in 423 patients with pT3N0 prostate cancer.
Petrovich Z; Lieskovsky G; Langholz B; Jozsef G; Streeter OE; Skinner DG
Int J Radiat Oncol Biol Phys; 2002 Jul; 53(3):600-9. PubMed ID: 12062603
[TBL] [Abstract][Full Text] [Related]
29. Radical prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathologic findings on biochemical disease-free outcome.
Zietman AL; Edelstein RA; Coen JJ; Babayan RK; Krane RJ
Urology; 1994 Jun; 43(6):828-33. PubMed ID: 7515206
[TBL] [Abstract][Full Text] [Related]
30. Prostate cancer disease-free survival after radical retropubic prostatectomy in patients older than 70 years compared to younger cohorts.
Malaeb BS; Rashid HH; Lotan Y; Khoddami SM; Shariat SF; Sagalowsky AI; McConnell JD; Roehrborn CG; Koeneman KS
Urol Oncol; 2007; 25(4):291-7. PubMed ID: 17628294
[TBL] [Abstract][Full Text] [Related]
31. Contemporary preoperative parameters predict cancer-free survival after radical prostatectomy: a tool to facilitate treatment decisions.
Nelson CP; Dunn RL; Wei JT; Rubin MA; Montie JE; Sanda MG
Urol Oncol; 2003; 21(3):213-8. PubMed ID: 12810209
[TBL] [Abstract][Full Text] [Related]
32. The results of radical prostatectomy at a community hospital during the prostate specific antigen era.
Smitt MC; Heltzel M
Cancer; 1996 Mar; 77(5):928-33. PubMed ID: 8608486
[TBL] [Abstract][Full Text] [Related]
33. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
[TBL] [Abstract][Full Text] [Related]
34. Isolated local recurrence is rare after radical prostatectomy in men with Gleason 7 prostate cancer and positive surgical margins: therapeutic implications.
Han M; Pound CR; Potter SR; Partin AW; Epstein JI; Walsh PC
J Urol; 2001 Mar; 165(3):864-6. PubMed ID: 11176487
[TBL] [Abstract][Full Text] [Related]
35. Seminal vesicle involvement after radical prostatectomy: predicting risk factors for progression.
Salomon L; Anastasiadis AG; Johnson CW; McKiernan JM; Goluboff ET; Abbou CC; Olsson CA; Benson MC
Urology; 2003 Aug; 62(2):304-9. PubMed ID: 12893340
[TBL] [Abstract][Full Text] [Related]
36. Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8-10 cancers.
Boorjian SA; Karnes RJ; Rangel LJ; Bergstralh EJ; Frank I; Blute ML
BJU Int; 2008 Feb; 101(3):299-304. PubMed ID: 17922854
[TBL] [Abstract][Full Text] [Related]
37. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H
BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824
[TBL] [Abstract][Full Text] [Related]
38. Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era.
Ung JO; Richie JP; Chen MH; Renshaw AA; D'Amico AV
Urology; 2002 Sep; 60(3):458-63. PubMed ID: 12350484
[TBL] [Abstract][Full Text] [Related]
39. Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma.
Gettman MT; Pacelli A; Slezak J; Bergstralh EJ; Blute M; Zincke H; Bostwick DG
Urology; 1999 Sep; 54(3):479-85. PubMed ID: 10475358
[TBL] [Abstract][Full Text] [Related]
40. Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not?
Choo R; Hruby G; Hong J; Hong E; DeBoer G; Danjoux C; Morton G; Klotz L; Bhak E; Flavin A
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):674-80. PubMed ID: 11849789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
